Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)

NCT03616899 is registered in ClinicalTrials.gov with Kala Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03616899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03616899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle In Subjects With Dry Eye Disease (STRIDE 3)
Lead sponsor
Kala Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 10, 2018
Completion date
February 5, 2020
Enrollment
901 (actual)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

kerato conjunctivitis sicca